Moderna stock rallies after patent settlement removes overhang

Shares of Moderna climbed in early trading on Wednesday after the vaccine maker agreed to a $950 million settlement with Arbutus Biopharma and Genevant Sciences, resolving long-running patent litigation tied to its Covid-19 shot.

The stock rose 5.4% to $52.50 in premarket trading, recovering from a 5.7% decline in the previous session.

By contrast, Arbutus shares fell more than 9%.

Futures tracking the S&P 500 were little changed as investors continued to monitor developments in the Middle East and the potential economic impact of a protracted conflict involving Iran.

Details of the settlement

Moderna said after Tuesday’s market close that it would pay $950 million to settle all litigation related to its Spikevax Covid-19 vaccine and mResvia respiratory syncytial virus vaccine.

The payment resolves claims that the company infringed patents covering lipid nanoparticle, or LNP, technology used to deliver mRNA into cells.

Under the agreement, Moderna will pursue an appeal in the federal circuit court, arguing that it has limited liability as a government contractor for its pandemic-related activities.

If the appeal fails, the company would owe an additional $1.3 billion to Arbutus and Genevant, payable within 90 days.

Moderna said it believes an additional loss is “not probable” and does not expect to record any further charge in its first-quarter earnings beyond the agreed settlement.

The $950 million payment will be recorded as a charge in the first quarter of 2026 and paid in a lump sum in the third quarter of that year.

As part of the deal, Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for certain mRNA vaccines targeting infectious diseases.

Genevant, a subsidiary of Roivant Sciences, will also provide a covenant not to sue over specified patents and products, effectively ending all patent-infringement litigation between the parties.

Removing uncertainty

Chief executive Stéphane Bancel said the agreement puts a legacy dispute from the pandemic era behind the company.

“Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna’s exciting near-term future,” he said.

Genevant chief executive James Heyes said the settlement recognises his company’s role in developing LNP technology.

“We are pleased with this settlement, which allows us to put this lengthy dispute behind us and remain focused on our mission,” he said.

Analysts say deal positive for Moderna

Analysts said the outcome appeared manageable relative to the company’s pandemic windfall.

Moderna generated roughly $45 billion to $50 billion in global Covid-19 vaccine revenue at the height of the crisis.

Evercore ISI analyst Cory Kasimov said investor expectations had varied widely, with some bearish scenarios assuming significantly higher payouts.

"Against that backdrop, the settlement appears manageable and eliminates a meaningful tail risk," Kasimov, who rates the stock at In Line with a price target of $35, added.

"We see the news as incrementally positive for Moderna."

Jefferies analyst Andrew Tsai described the agreement as removing the worst-case scenario of double-digit royalty rates and eliminating future royalty risk for upcoming Covid and combination Covid-flu vaccines.

The deal is positive for Moderna because the total payment works out to a very small share of the company's roughly $48 billion in past global vaccine sales, matching Moderna's earlier expectations, said Tsai.

Financial outlook and pipeline focus

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash equivalents, along with access to up to $900 million under its existing credit facility.

The resolution of the legal dispute comes as investors look beyond Moderna’s core respiratory vaccine business, which has faced slowing demand.

Shares have risen 69% this year, buoyed by optimism that the company’s oncology pipeline and broader mRNA platform could drive the next phase of growth.

For now, the settlement appears to have lifted a significant legal cloud, allowing investors to refocus on Moderna’s longer-term strategy.